Clinical trial
BMS-562247 in Subjects Undergoing Elective Total Knee Replacement Surgery
NCT00097357 · Bristol-Myers Squibb, Industry · Completed
Key facts
| NCT number | NCT00097357 |
|---|---|
| Title | BMS-562247 in Subjects Undergoing Elective Total Knee Replacement Surgery |
| Official title | A Phase 2 Randomized, Double-Blinded (BMS-562247 and Enoxaparin), Active-Controlled (Enoxaparin and Warfarin), Parallel-Arm, Dose-Response Study of the Oral Factor Xa Inhibitor BMS-562247 in Subjects Undergoing Elective Total Knee Replacement Surgery |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Venous Thrombosis, Pulmonary Embolism |
| Intervention type | Drug |
| Interventions | Apixaban, Enoxaparin, Warfarin, Enoxaparin Placebo, Apixaban Placebo |
| Enrollment | 1,238 |
| Start date | Oct 1, 2004 |
| Primary completion | Dec 1, 2005 |
| Completion | Dec 1, 2005 |
| First posted | Nov 23, 2004 |
| Last update posted | Mar 2, 2010 |
| Countries | Argentina, Australia, Canada, Denmark, Israel, Mexico, Poland, Puerto Rico, United States |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: